Loss of miR-200c:  A Marker of Aggressiveness and Chemoresistance in Female Reproductive 
Cancers by Cochrane, Dawn R. et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2010, Article ID 821717, 12 pages
doi:10.1155/2010/821717
Research Article
Loss of miR-200c: A Marker of Aggressiveness and
Chemoresistancein Female Reproductive Cancers
Dawn R.Cochrane,ErinN. Howe,Nicole S.Spoelstra,andJenniferK. Richer
Department of Pathology, Denver School of Medicine, University of Colorado, Aurora CO, 80045, USA
Correspondence should be addressed to Jennifer K. Richer, jennifer.richer@ucdenver.edu
Received 1 June 2009; Accepted 26 September 2009
Academic Editor: Phillip J. Buckhaults
Copyright © 2010 Dawn R. Cochrane et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
We focus on unique roles of miR-200c in breast, ovarian, and endometrial cancers. Members of the miR-200 family target ZEB1,
a transcription factor which represses E-cadherin and other genes involved in polarity. We demonstrate that the double negative
feedback loop between miR-200c and ZEB1 is functional in some, but not all cell lines. Restoration of miR-200c to aggressive
cancer cells causes a decrease in migration and invasion. These eﬀects are independent of E-cadherin status. Additionally, we
observe that restoration of miR-200c to ovarian cancer cells causes a decrease in adhesion to laminin. We have previously reported
that reintroduction of miR-200c to aggressive cells that lack miR-200c expression restores sensitivity to paclitaxel. We now prove
that this ability is a result of direct targeting of class III beta-tubulin (TUBB3). Introduction of a TUBB3 expression construct
lacking the miR-200c target site into cells transfected with miR-200c mimic results in no change in sensitivity to paclitaxel. Lastly,
we observe a decrease in proliferation in cells transfected with miR-200c mimic, and cells where ZEB1 is knocked down stably,
demonstrating that the ability of miR-200c to enhance sensitivity to paclitaxel is not due to an increased proliferation rate.
1.Introduction
Speciﬁc miRNAs have been found to be expressed in cell
type-speciﬁc manner, at speciﬁc developmental stages, and
in disease states including cancer [1, 2]. During the initiation
and progression of cancer, miRNAs have been observed to
act as oncogenes or tumor suppressors [3, 4]. While some
miRNAs are overexpressed in cancers, the majority appear
to be lost and often localize to fragile sites [5]. Diﬀerences
in the miRNA expression proﬁles of normal compared to
cancerous tissue of the endometrium, breast and ovary have
been documented [6–11]. MiRNAs can aﬀect the expression
of a large number of proteins, including those involved in
pathwaysrelevanttocancer,suchasapoptosis,migrationand
metastatis. Thus, miRNAs hold promise as biomarkers for
several types of cancer [12, 13].
Epithelial to mesenchymal transition (EMT) is a normal
process that occurs during development in which individual
cells or groups of cells become motile. The same process is
thought to be used by cancer cells during tumor progression
to enable them to become more motile and thus more
metastatic [14]. EMT involves reprogramming of the cells
by transcription factors such as ZEB1, SIP1 (ZEB2), Twist,
Snail, and Slug [15]. A hallmark of EMT is loss of E-cadherin
expression, loss of polarity, acquisition of mesenchymal
markers, and increased motility [16, 17]. Both ZEB1 and
the closely related ZEB2 bind E-box like sequences in the E-
cadherin promoter, recruit the corepressor CtBP and thereby
repressE-cadherin[18].ZEB1alsorepressesadditionalgenes
involvedinpolarity[16].ZEB1expressionisconﬁnedtocells
of mesenchymal origin, while normal epithelial cells and low
grade carcinomas do not express ZEB1. However, we and
others have shown that in high grade, aggressive carcinomas
that have undergone EMT, ZEB1 can be expressed, leading to
loss of E-cadherin [19–22].
Several miRNAs have been implicated in the process of
EMT,amongthemarethemembersmiR-200family[23–25].
This family contains ﬁve members (miR-200a, -200b, -200c,
-141 and, -429) which are highly homologous. Originally,
miR-200c was reported to directly bind ZEB1 and cause
degradation of the mRNA, resulting in an upregulation of
E-cadherin [26]. Subsequently, other reports have shown2 Journal of Oncology
that all members of the miR-200 family, since they share a
high degree of homology especially in their seed sequence,
are capable of repressing both ZEB1 and ZEB2 [27–29].
We have demonstrated that miR-200c represses not only
ZEB1/2, but a program of transcripts normally expressed
only in cells of mesenchymal origin [30]. Since members of
the miR-200 family are responsible for repressing ZEB1 and
ZEB2 as well as other mesenchymal genes, these miRNAs are
considered “guardians of the epithelial phenotype.” MiR-200
family members are therefore thought to be expressed in an
epithelial cell-speciﬁc manner in normal tissues. Recently,
the ability of ZEB1 to transcriptionally repress expression
of miR-200 family members has been documented [31,
32]. This double negative feedback loop between miR-200
family members and ZEB1 allows for plasticity between the
epithelial and mesenchymal states [33].
In this paper, we focus on the role of miR-200c in breast,
ovarian, and endometrial cancers. The mutual repression
between ZEB1 and miR-200c is functional in some, but not
allcellsthatwehavetested.IncreasingmiR-200clevelscauses
a decrease in adhesion to laminin. We demonstrate that the
decrease in migration and invasion observed when miR-200c
is reintroduced to cancer cells that lack it is independent
of restoration of E-cadherin. Lastly, we have previously
demonstrated that class III beta tubulin (TUBB3) is directly
controlledbymiR-200c.ExpressionofTUBB3isknowntobe
acommonmechanismofresistancetomicrotubule-targeting
agents in many types of cancer. Here, we present conclusive
data that repression of TUBB3 is the mechanism whereby
miR-200c restores sensitivity to paclitaxel. Taken together,
these data demonstrate that loss of miR-200c is a marker for
chemoresistance and aggressiveness in breast, ovarian, and
endometrial cancers.
2.MaterialsandMethods
2.1. Cell Culture. Hec50 cells, representing the more aggres-
sive Type II endometrial cancers [19], were cultured in
DMEM with 10% FBS, and 2mM L-glutamine. MDA-MB-
231 are a triple negative breast cancer cell line and were
grown in media containing 5% FBS, HEPES, nonessential
amino acids, L-glutamine, penicillin, streptomycin, and
insulin. Hey cells were grown in RPMI with 5% FBS. All cells
w e r eg r o w ni na3 7
◦C incubator with 5% CO2.T h ei d e n t i t y
of all the cell lines was conﬁrmed by DNA proﬁling using the
Identiﬁler Kit (Applied Biosystems).
2.2. Transfections. Lipofectamine 2000 (Invitrogen) was
combined with pre-200c (miRNA mimic) or scrambled
negative control (Ambion) at a concentration of 60nM and
incubated in serum free RPMI for 20 minutes prior to
addition to Hey cells. Cells were incubated at 37
◦Cf o r4
hours before replacement of FBS to 10%. Protein and RNA
were harvested 48 hours posttransfection.
TUBB3 (from Fernando Cabral, University of Texas -
Houston Medical School) was cloned into pCI-neo. Tran-
sient transfection of 3.3μg of TUBB3 plasmid or empty
vector (pCI-neo, Promega) per well in a 6-well plate was
performed using lipofectamine 2000.
2.3. Generation of Stable Cell Lines. Transduction of cells
was performed using SMARTvectorTM shRNA Lentivral
Particles (Thermo Scientiﬁc Dharmacon). Each cell line was
transduced with 3 separate lentiviral constructs targeting
ZEB1 as well as two controls: SMARTvector Empty Vector
particles and SMARTvector Fireﬂy Luciferase Control parti-
cles. The former is a negative control and does not correlate
with gene silencing and the latter is a positive control target-
ingﬁreﬂyluciferaseplasmidsPGL2andPGL3.Allvectorsare
packaged and contain a TurboGFP and an SCMV promoter,
as well as a puromycin-resistance selectable marker.
MDA231 and Hec50 cells were plated at 3000cells/well
and 1500cells/well, respectively, in triplicate using 96 well
plates. The following day, media was replaced with 80μl
of fresh media containing 10μg/mL polybrene (Sigma).
The amount of viral particles/well was determined using
the following calculation: (MOI × CN)/VT, where MOI
(multiplicity of infection) = 10TU/cell, CN = number of
cells/well, and VT = stock viral titer of 104 TU/μL. Viral
particles were added in a total volume of 20μLt oe a c hw e l l .
The following day, transduction media was removed and
wells were rinsed with PBS and replaced with regular media.
Once conﬂuent, cells were trypsinized and replated in 48
well plates. At this point, antibiotic selection was initiated
and cells were ultimately expanded and maintained using
1μg/mL of puromycin (Sigma).
2.4. Immunoblotting. W h o l ec e l lp r o t e i ne x t r a c t sw e r ed e n a -
tured and 50μg separated on 8% SDS PAGE gels and
transferred to PVDF membranes. The membranes were
b l o c k e di n5 %m i l ki nT B S - T ,a n dt h e np r o b e do v e r n i g h ta t
4◦C. Primary antibodies were diluted in 5% milk in TBS-T.
The primary antibodies used were ZEB1 (rabbit polyclonal
from Dr. Doug Darling, University of Kentucky, 1 : 1500
dilution),E-cadherin(cloneNCH-38fromDAKO,1μg/mL),
TUBB3 (rabbit polyclonal PRB-435P from Covance, 1 : 5000
dilution), and α-tubulin (clone B-5-1-2 from Sigma, 1 :
20000 dilution). After incubation with appropriate HRP-
conjugated secondary antibody, bands were detected using
WesternLightningChemiluminescenceReagentPlus(Perkin
Elmer).
2.5. Real Time RT-PCR. RNA was harvested from cells using
Trizol (Invitrogen) as per the manufacturer’s instructions.
Prior to generating cDNA, mRNA was treated with DNase1
(Invitrogen) for 15 minutes at room temperature. RNA
was reverse transcribed into cDNA in a reaction containing
reaction buﬀer, dNTPs, RNAse inhibitor (Applied Biosys-
tems), random hexamers, and 200U of MuLV-RT (Applied
Biosystems). The reaction proceeded at 22
◦Cf o r1 0m i n u t e s ,
then at 37
◦C for one hour. For normalization, real time
RT-PCR was performed on the cDNA using eukaryotic
18S rRNA endogenous control primers and FAM-MGB
probe (Applied Biosystems). TaqMan MicroRNA Reverse
Transcription kit was used to generate cDNA for real time
RT-PCR reaction in conjunction with a miR-200c speciﬁc
primer and probe (ABI, assay ID 002300). The reverse
transcription primer for miR-200c is a hairpin primer which
is speciﬁc for the mature miRNA and will not bind to theJournal of Oncology 3
precursor molecules. Reported values are the means and
standard errors of 3 biological replicates.
The relative mRNA or miRNA levels were calculated
using the comparative Ct method (ΔΔCt). Brieﬂy, the cycle
threshold (Ct) values for the rRNA were subtracted from Ct
values of the target gene to achieve the ΔCt value. The 2−ΔCt
was calculated for each sample and then each of the values
was then divided by a control sample to achieve the relative
miRNA levels (ΔΔCt).
2.6. Migration and Invasion Assays. The assays were per-
formed on MDA-MB-231 stable empty vector or shZEB1 #2,
or Hey cells transiently transfected with the miR-200c mimic
for 48 hours. Cells were serum starved for 12 hours prior to
performing the assay. BD BioCoat Control Insert Chambers
24-well plate with 8 micron pore size and BD BioCoat
Matrigel Invasion Chambers were used for migration and
invasion assays, respectively. After starvation, cells were
removedfromtheplateand50000Heycellsor250000MDA-
MB-231 cells were plated in 0.5mL media with 0.5% FBS
in the upper chamber. In the lower chamber 0.8mL of 50%
conditioned media plus 50% complete media containing an
additional 10% FBS was used as an attractant. Hey cells
were incubated for 24 hours and MDA-MB-231 cells for
4 8h o u r sa t3 7
◦C. Migrating or invading cells on the lower
surface of the membranes were stained with Diﬀ-Quik stain
(Fisher)andcountedmanuallyusingImageProPlussoftware
(Mediacybernetics Inc.).
2.7. Adhesion Assays. Adhesion assays were performed using
InnoCyte ECM Cell Adhesion Assays (Calbiochem) for
Collagen IV, Fibronectin, Basement Membrane Complex
and Laminin. To each well 50000 cells were added and
the plates were incubated at 37
◦C for 1.5 hour. The wells
were gently washed with PBS before adding the Calcein-
AM solution. The plates were incubated for 1 hour at 37
◦C,
and ﬂuorescence was read with an excitation wavelength of
485nm and an emission wavelength of 528nm. The relative
ﬂuorescent units were plotted, and the error bars represent
standard error of the mean over four replicates.
2.8.ClonogenicAssay. Heycellswereplatedinto6-wellplates
at a density of 2000 cells per well. Twenty-four hours after
plating, the cells were treated with 0, 1, 2, 3, 4, or 5nM
paclitaxel (Sigma) in triplicate. The cells were incubated at
37
◦C for 8 days before ﬁxing and staining with crystal violet.
Photosweretakenoftheplatesandtheimagesanalyzedusing
ImageJ software (NIH). The average number of colonies
and the average total area was plotted, with error bars
representing the standard error of the mean over the three
replicates.
2.9. Cell Death ELISAs. Hec50 cells were transfected with
the miR-200c mimic as described previously for the Hey
cells. Twenty-four hours after transfection, cells were treated
with 0, 15, 20 or 25nM paclitaxel (Sigma). Twenty-four
hours after treatment, the Cell Death ELISA (Roche) which
recognizes mono- and oligonucleosomes in the cytoplasm of
dyingcellswasperformedaspermanufacturer’sinstructions.
2.10. Proliferation Assays. Cells were plated into 6-well plates
(4000 Hey cells/well and 6000 MDA-MB-231 or Hec50
cells/well). At time points indicated, cells were trypsinized
and counted using the Vi-cell Cell Viability Counter (Beck-
man Coulter).
3. Results
3.1. Reciprocal Repression of miR-200c and ZEB1 Occurs in
Some but Not All Cell Types. Just as members of the miR-
200 family can repress ZEB1 by degradation of its transcript,
ZEB1 can repress expression of the miR-200 family members
bybindingtoE-boxeswithintheirpromoterregions[31,32];
see Figure 1(a). Directly increasing miR-200c levels in Hey
cells (aggressive serous ovarian cell line) by transfection
of a miR-200c mimic (pre-200c) results in repression of
ZEB1 expression (Figure 1(b)). Although ZEB1 is a repressor
of E-cadherin, we did not observe E-cadherin expression
induced by the repression of ZEB1 in these cells (data
not shown). However there are several other mechanisms
through which E-cadherin can be lost including methylation
of the promoter [34, 35] and chromosomal deletion [36,
37]. In contrast, we have previously shown that transient
transfection of the miR-200c mimic into MDA-MB-231
(an aggressive triple negative breast cancer cell line) and
Hec50 (an aggressive Type 1 endometrial cancer cell line)
causes a marked repression of ZEB1 and a restoration of
E-cadherin expression [30]. Presently, we stably transduced
lentiviral shRNAs targeting ZEB1 into these two cell lines
(Hec50 and MDA-MB-231). While two of the shRNAs did
not decrease ZEB1 protein, shRNA #2 caused an almost
complete repression of ZEB1 expression resulting in re-
expression of E-cadherin in both cell lines (Figures 2(c) and
2(d)). Intriguingly, while knock down of ZEB1 in MDA-
MB-231 cells causes the expected increase in miR-200c levels
(indicative of the reciprocal regulation), no such increase is
observed in Hec50 cells. This suggests that while reciprocal
repression of miR-200c and ZEB1 occurs in some cell lines, it
does not occur in all.
3.2. Restoration of miR-200c to Aggressive Cancer Cells Results
in Decreased Migration, Invasion, and Cell Adhesion. It has
been previously shown that the miR-200 family members
cause a decrease in cell migration and invasion [27, 29, 30].
We observe a decrease in migration and invasion in the
MDA-MB-231 cells in which ZEB1 has been knocked down,
resulting in an increase in miR-200c levels. In the MDA-
MB-231 cells there is 52% decrease in migration and a 50%
decrease in invasion in the shZEB1 #2 containing cells in
which ZEB1 is completely knocked down versus luciferase
control (Figures 2(a) and 2(b)). We show here that the same
holds true in the aggressive ovarian cancer Hey cell line. This
cell line is highly migratory and invasive, and reintroduction
of miR-200c to these cells results in an 83% decrease in
migration and a 79–86% decrease in invasion compared to
negative controls (Figures 2(c) and 2(d)). However, it is
interesting to note that the eﬀect on migration and invasion
caused by miR-200c is independent of the E-cadherin status
of the cells, since unlike the MDA-MB-231 cells, Hey cells4 Journal of Oncology
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Figure 1: Reciprocal repression between ZEB1 and miR-200c occurs in some, but not all cell types. (a) Schematic of the mutual repression of
ZEB1 and miR-200c. (b) Western blotting for ZEB1 and α-tubulin loading control, and real time RT-PCR for miR-200c in Hey ovarian cells
transiently transfected with a miR-200c mimic. Real time RT-PCR for miR-200c and western blotting for ZEB1, E-cadherin, and α-tubulin
in MDA-MB-231 breast cancer cells (c), and Hec50 endometrial cancer cells (d) stably transfected with shRNA lentiviral vector targeting
ZEB1 (shZEB), luciferase (shLuciferase), or the empty vector (shRNA EV).
donotregainE-cadherinexpressioninresponsetodecreased
ZEB1 levels.
While E-cadherin protein aﬀects epithelial cell-cell con-
tact, we also wished to determine if miR-200c aﬀects
adhesion to substrates as measured by ﬂuorescent adhesion
assays. Hey cells transiently transfected with the miR-200c
mimic showed a small but statistically signiﬁcant decrease
in adhesion to basement membrane complex (BMC) and
laminin(Figures3(a)and3(b)).Thereisalsoatrendtowards
decreased adhesion to collagen IV (Figure 3(c)); however,
this did not reach statistical signiﬁcance. No diﬀerence in
adhesion to ﬁbronectin was observed (Figure 3(d)). Since
there was an aﬀect on adhesion to BMC and laminin in
ovariancancercellswithhighmiR-200clevels,weperformed
the adhesion assay with the Hec50 and MDA-MB-231 cells
in which ZEB1 had been stably knocked down. We again see
a decrease in adhesion to BMC and laminin in the MDA-
MB-231 cells; however, only the decrease in BMC binding
is statistically signiﬁcant (Figures 3(e) and 3(f)). In contrast
to the Hey and MDA-MB-231 cells, there was no decrease
in adhesion to either substrate in the Hec50 cells in which
ZEB1 is knocked down (data not shown), but there is not a
concomitant increase in miR-200c, as shown in Figure 1(d).
This result suggests that the eﬀects on adhesion may be
mediated through miR-200c.
3.3. Increased Chemosensitivity to Paclitaxel with miR-200c
Expression. We have previously demonstrated that miR-200c
expression causes increased chemosensitivity to microtubule
targeting agents such as paclitaxel. While the ELISA cell
death assay that we have used previously to demonstrate
this property of miR-200c is a short-term assay, we conﬁrm
here, in a relatively long-term clonogenic assay, that there
is increased sensitivity of Hey cells to paclitaxel when
transfected with pre-200c (Figure 4(a)). We observe a 49–
55% decrease in total area and a 67–70% decrease in the
number of colonies in the pre-200c treated cells versus the
negativecontrolwith5nMpaclitaxeltreatment(Figures4(b)Journal of Oncology 5
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Figure 2: Increased miR-200c decreases migration and invasion, not necessarily dependent on restoration of E-cadherin. Migration (a) and
invasion (b) assays for MDA-MB-231 cells stably expressing an shRNA targeting ZEB1 with representative images below. Migration (c) and
invasion (d) assays in Hey cells transiently transfected with a miR-200c mimic. Asterisks indicate a statistically signiﬁcant diﬀerence (P<. 05,
Student’s t-test) versus negative controls.
and 4(c)). As the assay is conducted over a relatively long
period of time, the maximum dose of paclitaxel used is
relatively small compared to what is used in the assays that
look at acute toxicity (i.e., 24 hours). At doses of paclitaxel of
10nM and higher, no colonies are formed in the assay (data
not shown).
We have previously implicated the ability of miR-200c to
directly target TUBB3 (class III beta tubulin) as being the
mechanism responsible for the increased chemosensitivity
to microtubule targeting agents. TUBB3 is normally only
expressed in neuronal cells; however aberrant expression of
TUBB3 in several diﬀerent types of cancers has been shown
to cause resistance to paclitaxel [38–43]. We demonstrated
that miR-200c directly targets TUBB3 for degradation. To
deﬁnitively test whether TUBB3 is responsible for the miR-
200c-mediated increase in chemosensitivity to paclitaxel, we
transfected cells with a TUBB3 construct lacking its 3’ UTR
(containing the miR-200c binding site) which is therefore
not able to be targeted by miR-200c. Transfection of this
exogenous TUBB3 construct does not aﬀect the transfection
of the miR-200c mimic, nor its ability to downregulate
ZEB1 and upregulate E-cadherin (Figures 5(a) and 5(b))i n
Hec50 cells. When the Hec50 cells are transfected with an
empty vector (no exogenous TUBB3) in addition to miR-
200c mimic, there is a statistically signiﬁcant increase in
sensitivity to paclitaxel as measured in a cell death ELISA; see
Figure 5(c). However, when the cells are transfected with the
TUBB3 expression vector lacking its 3’ UTR, the enhanced
sensitivity to paclitaxel is lost; see Figure 5(d). Therefore,
expression of exogenous TUBB3 lacking the miR-200c target
site reverses the chemosensitivity to paclitaxel caused by
increased miR-200c expression.6 Journal of Oncology
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Figure 3: Increased miR-200c levels decrease adhesion to substrates. Fluorescent adhesion assays of Hey cells to (a) basement membrane
complex, (b) laminin, (c) collagen type IV, and (d) ﬁbronectin. Adhesion of MDA-MB-231 cells to (e) basement membrane complex and (f)
laminin. Asterisks indicate a statistically signiﬁcant diﬀerence (P < .05, Student’s t-test) versus the negative controls.
It can be argued that cells with increased proliferation
would be more sensitive to microtubule poisons and
that could be an alternative explanation for the observed
chemosensitivity upon restoration of miR-200c. We
therefore performed proliferation assays in the three cell
types and found decreased proliferation in all three (Figures
6(a), 6(b),a n d6(c)). Since the decrease in proliferation is
observed in all three cell types, including the Hec50s where
there was no increase in miR-200c levels, it is likely that the
eﬀects on proliferation occur via ZEB1 and not by miR-200c.
The fact that the increase in chemosensitivity is found in
cells that are proliferating more slowly than the negative
controls demonstrates that increased proliferation is not the
mechanism behind the increase in chemosensitivity.
4. Discussion
In this paper we build on our previous work to further
characterizetherolethatlossofmiR-200cplaysingenerating
an aggressive cancer phenotype. We focus on ovarian,Journal of Oncology 7
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Figure 4: Chemosensitivity to paclitaxel induced by miR-200c expression. (a) Clonogenic assay in Hey cells either mock transfected,
transiently transfected with a negative control, or miR-200c mimic and treated with 0–5nM paclitaxel. The total area (b) and number
of colonies (c) at 5nM paclitaxel are quantiﬁed. Asterisks indicate statistically signiﬁcant diﬀerence (P < .05, Student’s t-test) versus negative
controls.
endometrial,andbreastcancer.ThemiR-200familyiscrucial
for the maintenance of the epithelial phenotype. ZEB1 is
normally only expressed in cells of mesenchymal origin;
however, its aberrant expression is observed in cancers that
have undergone EMT. ZEB1 (and the closely related ZEB2)
transcripts are targeted by miR-200c and the other miR-200
family members. Interaction of any of the miR-200 family
memberswiththeZEBtranscriptsresultsindegradationand
inhibition of translation. Therefore the maintenance of miR-
200c expression in normal epithelial cells serves to prevent
ZEB1 and ZEB2 from being expressed. Since both ZEB1 and
ZEB2 repress genes involved in polarity, repression of these
proteins serves to maintain polarity, an important epithelial
cell characteristic. We have recently shown that in addition
to repressing ZEB1 and 2, miR-200c represses a program of
transcripts normally only expressed in cells of mesenchymal
andneuronalorigin,suchasﬁbronectin(FN1),neurotrophic
tyrosine kinase (NTRK2), quaking 1 (QKI), and TUBB3
[30]. Thus, miR-200c maintains epithelial cell characteristics
not only by maintaining polarity via repression of ZEB1 and
ZEB2, but also by repressing additional non-epithelial genes.
It has been recently demonstrated that miR-200c and
ZEB1 regulate each other in a double-negative feedback loop
[31, 32]. The miR-200 family of miRNAs is expressed in two
clusters, one on choromosome 1p36.33 and the other on
chromosome 12p12.31. E-boxes are located in the promoter
region of each of these clusters. ZEB1 can bind these E-
boxes and directly repress all miR-200 family members [31].
Therefore, in cells that have undergone EMT, ZEB1 and 2
not only serve to repress genes involved in polarity, but also
repressthemiR-200familyandtherebyreleasetherepression
of many genes characteristic of the mesenchymal phenotype.
Central to the double feedback loop between miR-200c and
ZEB1 is TGF-β. During TGF-β-induced EMT, there is an
increase in Ets1 which binds to and activates the promoter
of ZEB1 [44]. Therefore, in a tumor microenvironment,
increased TGF-β levels are thought to result in an increase
of ZEB1 transcription to a point where it can overcome the8 Journal of Oncology
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Figure 5: Restoration of TUBB3 reverses miR-200c-mediated enhanced chemosensitivity to paclitaxel. (a) Western blots for ZEB1, E-
cadherin, TUBB3, and α-tubulin in Hec50 cells transiently transfected with a miR-200c mimic or negative controls and an expression vector
for TUBB3 or empty vector. (b) Real time RT-PCR for miR-200c. Cell death ELISA for cells transfected with a miR-200c mimic and an
empty vector (c) or TUBB3 expression vector (d) treated with various concentrations of paclitaxel. Asterisks indicate statistically signiﬁcant
diﬀerence (P < .05, Student’s t-test) versus negative controls.
repression caused by miR-200c. As ZEB1 protein begins to
be made, it can then repress the miR-200 family members,
resulting in progression through EMT [32].
We have previously shown that restoration of miR-200c
in Hec50 endometrial cells and MDA-MB-231 breast cancer
cells causes repression of ZEB1 and re-expression of E-
cadherin protein. Here we show that transfection of miR-
200c mimic into Hey cells, an aggressive serous ovarian cell
line, also causes a dramatic repression of ZEB1; however
no expression of E-cadherin was observed. To test whether
the double-negative feedback loop is intact in the Hec50
and MDA-MB-231 cells, these cells were infected with
lentivirus expressing an shRNA against ZEB1. In both cell
lines, eﬃcient knock down of ZEB1 was achieved, as was
re-expression of E-cadherin. In MDA-MB-231 cells, ZEB1
knock down resulted in an increase in miR-200c levels,
as would be expected from the negative feedback loop.
However, this was not the case in Hec50 cells, where there
was no increase in miR-200c. Whether the break in the
negative feedback loop is an anomaly of this particular
cell line remains to be tested. The mechanism behind the
phenomenon is also unknown; however, it does oﬀer an
opportunity to dissect the contribution of ZEB1 versus that
of miR-200c to the phenotype of the cells. For example,
signiﬁcantly decreased proliferation was observed in the
Hey cells transiently transfected with the miR-200c mimic
as well as in the MDA-MB-231 and Hec50 cells that have
ZEB1 stably knocked down, although miR-200c levels did
not rise in the Hec50s. Therefore it is likely that the
decrease in proliferation is due to the lack of ZEB1, not an
increase in miR-200c. Conversely, the decrease in adhesion
to the basement membrane complex and laminin was onlyJournal of Oncology 9
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Figure 6: Proliferation assay in Hey cells transiently transfected with a miR-200c mimic (a), or Hec50 cells (b), and MDA-MB-231 cells
(c) stably expressing an shRNA against ZEB1. Asterisks indicate statistically signiﬁcant diﬀerence (P < .05, Student’s t-test) versus negative
controls.
observed in the Hey and MDA-MB-231 cells, and not the
Hec50s, suggesting that this phenotype is a function of miR-
200c expression rather than ZEB1.
We and others have previously shown that restoration
of miR-200c to cancer cells that do not express it causes
a decrease in invasion and migration [27, 30]. Here we
show that knock down of ZEB1 in MDA-MB-231 cells,
which causes an increase in miR-200c, negatively aﬀects
migration and invasion. Furthermore, we show that restora-
tion of miR-200c in Hey ovarian cancer cells results in a
dramatic decrease in migration and invasion even though
E-cadherin is not restored in these cells, despite complete
repression of ZEB1. Loss of E-cadherin expression can
result from mechanisms other than ZEB1 transcription
repression, including chromosomal deletion and promoter
hypermethylation [34–37]. Possibilities for its continued
absenceinthesecellsincludepromotermethylationsuchthat
even when repression by ZEB1 is relieved, E-cadherin will
not be expressed, or perhaps levels of another transcriptional
repressor such as Snail or Twist remain high and repress E-
cadherin. Regardless of the mechanism, the eﬀects of miR-
200c on invasion and migration appear to be independent of
E-cadherin status. While E-cadherin is involved in epithelial
cell-cell adhesion and its expression has been shown to
negatively aﬀect migration and invasion [45, 46], increased
miR-200c is able to decrease migration and invasion on its
own. We have previously observed that restoration of miR-
200c aﬀects genes involved in cell motility and invasion such
as ARHGDIB, NTRK2, EPHB1, and FN1 [30].
We demonstrate that miR-200c causes a decrease in
adhesion to basement membrane complex, laminin, and
perhaps collagen type IV. This observation is particularly10 Journal of Oncology
relevant to ovarian cancer because the cancerous cells adhere
to sites within the peritoneal cavity. During the progression
of cancer there is switching of the expression patterns of the
cell surface adhesion molecules, such as the cadherins and
integrins [47–49]. Although the change in the number of
adherent cells appears modest, this might play a signiﬁcant
role in developing a potential treatment for ovarian cancer.
The ability of ovarian cancer cells to spread and adhere to
the peritoneal cavity is one of the major phenotypes of this
disease. A small change in ability of the cells to adhere might
reﬂect a great decrease in the tumor burden and/or increase
theabilitytodebulkthetumor.Theseresultsareindependent
of E-cadherin expression since the decrease in adhesion is
observed in both the MDA-MB-231 cells (where E-cadherin
expression is regained with increased miR-200c) and in Hey
cells, where it is not.
Clonogenic assays reveal that there is an increase in
chemosensitivity to paclitaxel with increased miR-200c lev-
els.Indeed,acquiredresistancetopaclitaxelinovariancancer
cells has been shown to be associated with EMT, resulting in
an aggressive phenotype [50]. Clinically, aberrant expression
of TUBB3 (not normally expressed in epithelial cells) has
been found to be associated with resistance to taxanes [38–
41]. We have previously shown that TUBB3 is a direct target
of miR-200c and suggested that its repression by miR-200c
is the mechanism behind the ability of miR-200c to increase
chemosensitivity to microtubule targeting agents [30]. Here,
we perform the deﬁnitive experiment to prove that miR-
200c-mediated TUBB3 downregulation is indeed the cause
of the enhanced chemosensitivity. We utilized exogenous
TUBB3 lacking its 3’UTR such that it cannot be targeted by
miR-200candshowthatresistancetopaclitaxelismaintained
even in the presence of miR-200c. In contrast, endogenous
TUBB3 is reduced when miR-200c is added, resulting in
enhanced chemosensitivity to paclitaxel.
Microtubule targeting agents such as paclitaxel work
more eﬃciently in cells that are rapidly dividing. Conse-
quently, it could be argued that the increase in chemosensi-
tivity caused by miR-200c is due to increased proliferation.
However, we show that increase of miR-200c or direct
knockdown of ZEB1 results in decreased proliferation in
three diﬀerent types of cancer cells. It is therefore the
downregulation of TUBB3, not an increase in proliferation
that is responsible for the enhanced chemosensitivity to
taxanes observed with restoration of miR-200c to resistant
cancer cells.
5. Conclusions
MiR-200c expression serves to maintain the epithelial phe-
notype in well-diﬀerentiated, low-grade, breast, ovarian, and
endometrial cancer cells. This phenotype includes decreased
adhesion to laminin and decreased migration and invasion.
Furthermore we ﬁnd that not all of miR-200c’s actions can
be attributed to the restoration of E-cadherin via targeting of
ZEB1. We further prove that miR-200c-mediated repression
of TUBB3 is the cause of enhanced chemosensitivity to
microtubule targeting agents. Lastly we demonstrate that not
all cells exhibit the double negative feedback loop between
miR-200c and ZEB1 and that this can be exploited to identify
the distinct roles of miR-200c as compared to ZEB1.
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